Logo

Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

Share this

Incyte's Opzelura (ruxolitinib) Receives the US FDA's Approval for the Treatment of Atopic Dermatitis

Shots:

  • The approval is based on the TRuE-AD clinical trial program which consists of two P-III studies i.e.- TRuE-AD1 & 2 evaluating the safety and efficacy of Opzelura cream (1.5%- bid) vs vehicle (non-medicated cream) in 1200+ adolescents & adults aged ≥12yrs. with mild to moderate AD
  • The results showed that the patients achieved IGA-TS @8wks. (53.8% & 51.3% vs 15.1% & 7.6%) & clearer skin- reduction in itch from baseline @8wks. as measured by a ≥4-point reduction in the itch NRS4 (52.2% & 50.7% vs 15.4% & 16.3%) respectively
  • Opzelura is the first topical formulation of a JAK inhibitor approved in the US. The therapy is currently being evaluated is in the P-III TRuE-V clinical program for the treatment of vitiligo

Ref: Businesswire | Image: Reuters

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions